Introdução: A privação de sono (PdS) tem sido utilizada como um estratégia alternativa para o tratamento do Transtorno Depressivo Maior (TDM), contudo sua eficácia e efetividade carecem de estudos homogêneos e de bom delinemento para dar um grau de evidência científica para seu uso na prática diária. Assim sendo, desde a primeira publicação, em 1971, num relato de caso de um paciente com TDM grave tipo melancólico, por Plug e Tölle, o mesmo estava assintomático no dia seguinte à privação total de sono. Contudo, na noite seguinte de sono seus sintomas depressivos retornaram. Nestes quase 40 anos desde esta publicação houve dezenas de estudos em sua maioria relatos de caso, série de casos ou até estudos abertos só que misturando pacientes com TDM com Depressão Bipolar sem mesmo distinguir se tipo I ou II. A cafeína com seu efeito estimulador poderia ser uma alternativa para facilitar a privação de sono. No entanto, não há dados sobre o sua potencial influência no efeito antidepressivo da PdS. O objetivo deste estudo é avaliar o efeito da cafeína na PdS em pacientes deprimidos unipolares moderados a graves não psicóticos. Métodos: Ensaio Clínico randomizado, duplo cego, cruzado, comparando cafeína contra placebo em pacientes deprimidos moderados a graves submetidos à privação total de sono (PdS). Os pacientes foram avaliados por itens da escala de Lader, HAMD- 6 itens, CGI Severidade e Melhora Global. Resultados: Foram avaliados 20 pacientes. Os pacientes que usaram cafeína mantiveram o mesmo escore de energia pré e pós-privação de sono (item energético-letárgico da escala de Lader) enquanto os do grupo placebo diminuíram o escore de energia pós-privação de sono. (p = 0,0045). Não houve diferença entre o grupo cafeína e placebo nos demais itens da escala de Lader. Conclusão: O uso combinado de cafeína e PdS pode ser uma estratégia útil para manter os pacientes mais acordados sem o prejuízo do cansaço da PdS em pacientes ambulatoriais deprimidos. Contudo, mais estudos envolvendo pacientes que tenham 10 respondido à PdS são necessários para verificar se a cafeína também não interfere nos resultados deste grupo. / Introduction: Sleep deprivation (SD) has been used as an alternative approach to treat major depressive disorder (MDD), however the efficacy and the effectiveness needs studies with homogeneity and better delineament to strengthen the evidence based medicine to the use in the practical daily use. Besides, since the 1° puplication in 1971 of a case report, by Plug and Tölle, in that one patient with severe melancholic depressive disorder achieved remission in the next day after a total sleep deprivation. However his depressive sintomtology was back after the next night of sleep. Since this almost 40 years, a lot of papers were puplished, and the majority where case report, case reports and open trials with patients with MDD, bipolar depression without make difference between tipe I or II. Caffeine, due to its stimulating effect, could be an alternative to promote sleep deprivation. However, there are no data about its potential influence on the antidepressive effect of SD. The objective of this study is to assess the effect of caffeine on SD in non-psychotic patients with moderate to severe unipolar depression. Methods: Randomized, double-blind, crossover clinical trial comparing caffeine and placebo in moderate to severe depressed patients who underwent total sleep deprivation (SD). The patients were assessed with items of the Bond-Lader Scale, the 6-item Hamilton Depression Rating Scale (HAMD-6), and the Clinical Global Impression (CGI)-Severity/Improvement. Results: Twenty patients participated in this study. The patients who consumed caffeine presented the same score of energy before and after sleep deprivation (lethargicenergetic item of the Bond-Lader scale), while the patients in the placebo group had a reduced score of energy after sleep deprivation (p = 0.0045). There was no difference between the caffeine and placebo groups in the other items of the Bond-Lader scale. Conclusion: The combined use of caffeine and SD can be a useful strategy to keep the 12 patient awake without impairing the effect of SD on depressed outpatients. However, further studies involving patients who have responded to SD are needed in order to verify if caffeine also does not interfere with the results in this group.

A depressão periparto (PPD) é subtipo altamente prevalente e subdiagnosticado do transtorno depressivo maior (MDD), e causa um importante sofrimento para a mulher, sua família e seu filho. Uma interação complexa entre hormônios, neurotransmissores e fatores genéticos e ambientais pode estar envolvida na etiologia da PPD. Contudo, estudos de neuroimagem na PPD ainda são escassos, particularmente os que identificam alterações neuroquímicas. Sabe-se que a região do córtex pré frontal dorsolateral (dlPFC) está relacionada à funções executivas no circuito pré frontal, e juntamente com o giro do cíngulo anterior (ACG) faz parte das vias neuronais envolvidas no processamento emocional, desde a geração, regulação e reavaliação do estado afetivo. Existem evidências de que ambas as áreas estejam disfuncionais na MDD. A avaliação neuroquímica obtida pela espectroscopia de próton por ressonância magnética (MRS) permite inferir o metabolismo, a neurotransmissão e a viabilidade do tecido neuronal de interesse destas áreas fronto-límbicas. Objetivo: comparar puérperas com depressão periparto (grupo PPD) com puérperas saudáveis (grupo HP) quanto à avaliação neuroquímica no dlPFC esquerdo e no ACG bilateral. Métodos: 36 puérperas do grupo PPD e 25 puérperas do grupo HP foram submetidas à duas entrevistas psiquiátricas estruturadas e à aplicação de questionários e escalas psicométricas, sendo a segunda avaliação realizada seccionalmente à MRS. A MRS foi adquirida pro MRI com campo de 3 Tesla, estando o volume de interesse (VOI) posicionado no dlPFC esquerdo e no ACG bilateral e processada pelo software LCModel. Os resultados neuroquímicos expressos em valores absolutos e normalizados pela creatina (razão metabólito/creatina) foram analisados por ANCOVA, incluindo a idade, o tempo de puerpério e o tipo de contraceptivo, enquanto covariáveis. Resultados: No dlPFC, o grupo PPD apresentou menores valores de Glu/Cr (-0,17; p=0,05), Glx (-0,95 mM; p=0,04), Glx/Cr (-0,22; p=0,03), NAA (-0,60 mM; p<0,01), e NAA/Cr (-0,13; p=0,02) em relação ao grupo HP. No ACG, o uso de hormônios contraceptivos somente com progestágenos resultou em um aumento dos valores de Glu (2,18 mM; p=0,03), Glx (1,84 mM; p=0,03), e redução de Cho/Cr (-0,08; p=0,03) quando comparados ao grupo que não utilizou somente progestágenos, independentemente dos grupos HP e PPD. Conclusão: Os níveis reduzidos de Glu e NAA no grupo PPD estão relacionados, respectivamente, à disfunção metabólica glutamatérgica e neuroglial no dlPFC, o que pode explicar sintomas cognitivos também relacionados à PPD, tal como já verificado no MDD. O uso de hormônios contraceptivos com progestágenos isoladamente interferiu com a neuroquímica do ACG, mas não se relacionou com a PPD. Embora o aumento do glutamato possa sugerir uma hiperfuncionalidade do ACG, e a redução da Cho/Cr representar diminuição de \"turnover\" da membrana lipídica ou da transdução sináptica, seu significado clínico e fisiopatológico ainda é incerto. Estes resultados contribuem com a compreensão dos substratos neuroquímicos de PPD / Peripartum depression (PPD) is a highly prevalent subtype of major depressive disorder (MDD) related to a significant loss for mother, family and baby. An Interaction between hormones, genetic, and environmental factors must be involved in its etiology. However, neuroimaging studies on PPD are still rare, particularly those that identify neurochemical changes. However, neuroimaging studies in PPD are still rare, particularly those that identify neurochemical changes. It is known that the region of the dorsolateral prefrontal cortex (dlPFC) is related to executive functions in the prefrontal circuit, and together with the anterior cingulate gyrus (ACG) is part of the neural pathways involved in emotional processing, including the generation, regulation, and reappraisal of affective state. And, there is evidence that both areas are dysfunctional in MDD. The neurochemical evaluation obtained by spectroscopy of proton magnetic resonance (MRS) allows to infer metabolism, neurotransmission and the viability of the neuronal tissue of interest these frontal-limbic areas. Objective: Compare postpartum women with peripartum depression (PPD group) with healthy postpartum women (HP group) regarding the neurochemical evaluation in the left dlPFC and bilateral ACG. Methods: 36 postpartum women of PPD group and 25 postpartum women of the HP group were subjected to two structured psychiatric interviews and questionnaires and psychometric scales, with the second evaluation performed sectionally at MRS. The MRS was obtained by 3-T MRI system with the volume of interest (VOI) positioned on the left dlPFC and bilateral ACG and processed by LC Model software. The neurochemical results expressed in absolute values and normalized by creatine (reason metabolite/creatine) were analyzed using ANCOVA, including age, postpartum time, the type of contraceptive as covariates. Results: In the dlPFC, PPD group presented significantly lower values of Glu/Cr (-0.17; p=0.05), Glx (-0.95mM; p=0.04), Glx/Cr (-0.22; p=0.03), NAA (-0.60mM; p<0.01), and NAA/Cr (-0.13; p=0.02) than HP. In ACG, progestogens isolated contraceptive hormones use resulted in significantly increased Glu (2.18mM; p=0.03), Glx (1.84mM; p=0.03), and reduced Cho/Cr (-0.08; p=0.03), compared to women without use them, regardless of diagnostic groups. Conclusions: The reduced levels of Glu and NAA in the PPD group are related respectively to the glutamatergic and neuroglial metabolic dysfunction in the dlPFC, which may explain cognitive symptoms also related to PPD as already verified in MDD. Progestogens isolated contraceptive hormones use interfered with neurochemistry of ACG, but not associated with PPD. Although the increase of glutamate may suggest an overactive ACG, and lower Cho/Cr represent decrease of the lipid membrane turnover or synaptic transduction its clinical and pathophysiological significance remains uncertain. These results contribute to the understanding of the neurochemical substrates of PPD

Major depressive disorder (MDD) is a mood disorder majorly responsible for disability and mortality worldwide. With a lifetime prevalence of 15-20%, it is the main cause of functional impairment in Western societies as well as the fourth most debilitating illness in the world. Although the pathophysiology of MDD is not yet fully understood, some evidence that suggest the presence of a neuroanatomical deficiency have given rise to the theory of a specific imbalance in the monoamine neurotransmitters noradrenaline (NA) and/or serotonin (5-HT) levels in the brain. Overall, the various classes of antidepressant agents that have been developed to increase monoamine levels on the basis of this proposal have been successful. However, facts relating to prevalent escalation in the illness and recurring episodes of depression point towards a need to enhance clinical treatment. Most conventional antidepressants such as selective serotonin reuptake inhibitors (SSRI) and selective serotonin and noradrenaline inhibitors (SNRI) pose problems in symptomatic improvement. These include therapeutic lag, safety and tolerability issues, making more than 30% patients with MDD unable to reach adequate relief. In this respect, the action mechanism has moved beyond conventional SSRI and lead to the introduction of vilazodone, a novel antidepressant with an additional 5-HT1A partial agonist profile argued to be of potential benefit for a greater efficacy, faster onset of action and better tolerability. Using secondary data, this project aimed to evaluate the role of vilazodone as a SPARI-drug in the overall clinical treatment of MDD as well as its potential in addressing some of the most common obstacles in antidepressant treatment. Study results proved vilazodone’s efficacy to be superior to placebo. Patients across all studies showed significant improvement in depressive symptoms measured in MADRS and HAMD17. Vilazodone was also shown to be generally safe and tolerable but was not positively distinguished from placebo with regards to adverse effects. An overall, meaningful improvement in depressive symptoms was demonstrated in vilazodone, which reinforces its merit as an important treatment option for patients with MDD.

Background: Patients with borderline personality disorder (BPD) suffer from instability of their relationships, their affectivity and their identity. The purpose of the study was to investigate negative affects and identity disturbance in patients with BPD and in patients without personality disorder using questionnaire data and interview data. Sampling and Methods: Twelve patients with BPD and 12 patients with major depressive disorder without any personality disorder were assessed with the Structured Interview of Personality Organization (STIPO) and questionnaires (Inventory of Personality Organization, Beck Depression Inventory, State-Trait Anxiety Inventory). They were compared with respect to the frequency of negative affective verbal expressions using computerized content analysis methods. Results: BPD patients showed higher levels of anxiety, depression and identity diffusion in the questionnaires than major depressive disorder patients without personality disorder. However, they did not report more negative affective expressions in the interview. Patients with identity disturbance of both groups showed higher values of negative mood in the questionnaires, but less anger, less anxiety and less affective intensity in the interview. Conclusion: The preliminary findings indicate that patients with identity disturbance show high levels of negative affects in questionnaires but only few negative affects in the interview situation. More studies are needed to enhance the understanding of negative affects and identity disturbance in BPD. / Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich.

La stimulation magnétique transcrânienne répétée (SMTr) est une technique de neuromodulation utilisée dans le traitement de la dépression majeure. La stimulation thêta-burst intermittente (STBi), une forme spécifique de SMTr, bénéficie d’un temps de stimulation plus court. Ses mécanismes d’action et sa durée optimale de stimulation restent toutefois inconnus. En effet, en clinique, la durée standard de STBi tend à être allongée dans l’espoir d’augmenter les effets thérapeutiques. Cette hypothèse n’a cependant jamais été vérifiée empiriquement. Le présent mémoire vise ainsi à mieux comprendre les mécanismes neuronaux de la STBi du cortex dorsolatéral préfrontal gauche et à déterminer la durée optimale de stimulation parmi les trois durées les plus fréquemment utilisées : 600 (standard), 1200 et 1800 impulsions. La question est explorée chez 14 participants neurotypiques. Chaque participant a pris part aux trois conditions expérimentales lors de trois sessions distinctes. L’activité cérébrale induite a été mesurée par l’utilisation combinée de la stimulation magnétique transcrânienne et l’électroencéphalographie, via les potentiels évoqués par la SMT (PÉS) et les perturbations spectrales liées à l’évènement (PSLE). Ces mesures ont été comparées avant et après chaque condition à l’aide d’un modèle linéaire mixte. Pour l’ensemble des mesures de l’activité corticale, aucune différence significative n’a été obtenue entre les trois durées. Spécifiquement, la STBi a induit une réduction de l’amplitude de la majorité des PÉS et des PSLE de la bande thêta. Ainsi, le protocole STBi standard engendre une modification de l’activité cérébrale comparable aux durées prolongées, dénotant l’importance de répliquer cette étude auprès d’une population clinique. / Repetitive transcranial magnetic stimulation (rTMS) is a neuromodulation technique used as a treatment of major depressive disorder. Intermittent theta burst stimulation (iTBS), a specific kind of rTMS, offers a reduced stimulation duration. Yet, its mechanism of action and optimal duration are still largely unknown. In clinical settings, standard duration is often increased with the expectation of increasing therapeutic effects. However, this hypothesis has never been tested. This master thesis aims to provide better understanding of neuronal mechanism associated with iTBS on the left dorsolateral prefrontal cortex (DLPFC) of healthy participants and to determine the optimal stimulation duration over the three more commonly used durations in clinical practice: 600 (standard), 1,200 and 1,800 pulses. This was explored in 14 neurotypical participants who experienced each of the three conditions during three different sessions. The induced brain activity was measured combining transcranial magnetic stimulation and electroencephalography, via TMS evoked potentials (TEP) and event-related spectral perturbation (ERSP). These measures were compared before and after each condition using a mixed linear model. For the three durations, no significant difference was found in all cortical activity measures. Specifically, after iTBS, the amplitude of most of the TEPs, as well as of the ERSP of theta band, are reduced. Therefore, the iTBS standard protocol induces a modification of cortical activity which is similar to longer durations, showing the importance of replicating this study on a clinical population.

Identification of predictors of treatment response in patients with major depressive disorder (MDD) may facilitate improved disease management. Data were pooled from two 6-week, double-blind, placebo-controlled studies of extended-release quetiapine (quetiapine XR; 150 or 300 mg/day) as adjunct to ongoing antidepressant therapy. Effects of psychiatric history and baseline demographic and disease characteristics on efficacy outcomes (Week 6 Montgomery Åsberg Depression Rating Scale [MADRS] total score reduction) were evaluated in population subgroups (quetiapine XR both doses pooled, n = 616; placebo, n = 303). Baseline Clinical Global Impressions-Severity (CGI-S) score and previous depressive episodes on Week 6 MADRS total score change, and baseline MADRS individual item scores on Week 6 change in CGI-Improvement score, were also evaluated. No major differences between responders and non-responders to quetiapine XR were observed for patient characteristics or demographic and disease characteristics. No suggestion of a predictive association was found between baseline CGI-S score, number of depressive episodes, and baseline MADRS item scores and efficacy outcomes. These analyses showed no major differences between responders and non-responders, and no predictive association between the parameters assessed and efficacy outcomes for adjunct quetiapine XR in patients with MDD and an inadequate response to prior antidepressant therapy.

Background: Major depression is one of the most prevalent, disabling, and costly illnesses worldwide. Despite a 400% increase in antidepressant medication use since 1988, fewer than half of treated depression patients experience a clinically meaningful reduction in symptoms and uncertainty exists regarding how to successfully obtain symptom remission. Identifying homogenous subgroups based on clinically observable characteristics could improve the ability to efficiently predict who will benefit from which treatments. Methods: Latent class analysis and latent transition analysis (LTA) were applied to data from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study to explore how to efficiently identify subgroups comprised of the multiple dimensions of depression and examine changes in subgroup membership during treatment. The specific aims of this dissertation were to: 1) evaluate latent depression subgroups for men and women prior to antidepressant treatment; 2) examine transitions in these subgroups over 12 weeks of citalopram treatment; and 3) examine differences in functional impairment between women’s depression subgroups throughout treatment. Results: Four subgroups of depression were identified for men and women throughout this work. Men’s subgroups were distinguished by depression severity and psychomotor agitation and retardation. Severity, appetite changes, insomnia, and psychomotor disturbances characterized women’s subgroups. Psychiatric comorbidities, especially anxiety disorders, were related to increased odds of membership in baseline moderate and severe depression subgroups for men and women. After 12 weeks of citalopram treatment, depression severity and psychomotor agitation were related to men’s chances of improving. Severity and appetite changes were related to women’s likelihood of improving during treatment. When functional impairment was incorporated in LTA models for women, baseline functional impairment levels were related to both depression subgroups at baseline and chances of moving to a different depression subgroup after treatment. Conclusion: Depression severity, psychomotor disturbances, appetite changes, and insomnia distinguished depression subgroups in STAR*D. Gender, functional impairment, comorbid psychiatric disorders, and likelihood of transitioning to subgroups characterized by symptom improvement differed between these subgroups. The results of this work highlight how relying solely on summary symptom rating scale scores during treatment obscures changes in depression that might be informative for improving treatment response.

No description available.

No description available.

<p>This thesis presents research investigating structural neural correlates of major depressive disorder (MDD). Although there are clear clinical differences between early- and late-onset MDD, they are still subject to the same diagnostic criteria and treatment strategy. Whether these differences translate into differences in cortical structure was examined in this study. By directly comparing early-onset (EOD) and late-onset (LOD) patients, we test whether age-of-onset results in changes in the extent or spatial pattern of cortical thinning.</p> <p>Chapter 1 provides a general background on the cerebral cortex, followed with a focus on cortical thickness. Chapter 2 presents a comprehensive review of the clinical and neurobiological literature on major depressive disorder as it pertains to age-of-onset. Three working hypotheses regarding the differences between early- and late-onset depression are presented and discussed.</p> <p>The results presented in this thesis show that there are both differences and similarities in cortical thickness between patients with EOD and LOD, with differences reflecting spatial extent, region-specificity, and magnitude of thickness differences. We confirmed the hypothesis of greater thinning in the dorsal lateral prefrontal cortex in depressed patients compared to healthy controls. We also correlated cortical thickness with clinical variables, which resulted in the finding of a positive correlation in the posterior cingulate cortex with illness severity.</p> <p>Few studies have used age-of-onset as a factor, which may account for some of the heterogeneity and inconsistent results seen in studies of MDD. We found that depression onset in early life is associated with greater disturbances in cortical thickness than LOD, possibly reflecting atypical development. These results provide novel insights into vulnerability and how development of depression is differentially affected by age.</p> / Master of Science (MSc)